Single Ascending-Dose Study To Evaluate the Safety, Tolerability, and Pharmacokinetics of Sutezolid in Healthy Adult Subjects.
antimicrobial safety
pharmacokinetics
phase 1
safety
sutezolid
tuberculosis
Journal
Antimicrobial agents and chemotherapy
ISSN: 1098-6596
Titre abrégé: Antimicrob Agents Chemother
Pays: United States
ID NLM: 0315061
Informations de publication
Date de publication:
19 04 2022
19 04 2022
Historique:
pubmed:
15
3
2022
medline:
22
4
2022
entrez:
14
3
2022
Statut:
ppublish
Résumé
The primary objective of the study was to evaluate the safety and tolerability of single oral doses of sutezolid tablets administered under fasting conditions in healthy adult subjects. The secondary objective was to determine the pharmacokinetics (PK) of sutezolid and two metabolites, PNU-101603 and PNU-101244. Overall, sutezolid was well tolerated when administered as a 300-mg, 600-mg, 1,200-mg, or 1,800-mg dose in healthy adult subjects under fasting conditions. Maximum concentration (
Identifiants
pubmed: 35285241
doi: 10.1128/aac.02108-21
pmc: PMC9017382
doi:
Substances chimiques
Oxazolidinones
0
PNU-100480
0
Tablets
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0210821Références
Antimicrob Agents Chemother. 2009 Apr;53(4):1314-9
pubmed: 19075058
PLoS One. 2014 Apr 14;9(4):e94462
pubmed: 24732289
Eur J Pharm Sci. 2020 Aug 1;151:105421
pubmed: 32531349
PLoS Med. 2007 Jul 24;4(7):e238
pubmed: 17676945
N Engl J Med. 2020 Mar 5;382(10):893-902
pubmed: 32130813
Antimicrob Agents Chemother. 2015 Oct 26;60(1):270-7
pubmed: 26503656
J Med Chem. 1996 Feb 2;39(3):680-5
pubmed: 8576910
Antimicrob Agents Chemother. 2011 Feb;55(2):567-74
pubmed: 21078950
Clin Infect Dis. 2006 Apr 15;42(8):1111-7
pubmed: 16575728
Chest. 2006 Jul;130(1):261-72
pubmed: 16840411
J Infect Dis. 2010 Sep 1;202(5):745-51
pubmed: 20629533
Cochrane Database Syst Rev. 2019 Mar 20;3:CD012836
pubmed: 30893466
Diagn Microbiol Infect Dis. 2008 Dec;62(4):407-10
pubmed: 18929458
Pharm Res. 2000 Oct;17(10):1278-83
pubmed: 11145235